Clinical trial
Study of Epratuzumab (hLL2) in Patients With Waldenstrom's Macroglobulinemia
NCT00113802 · Gilead Sciences, Industry · Terminated
Key facts
| NCT number | NCT00113802 |
|---|---|
| Title | Study of Epratuzumab (hLL2) in Patients With Waldenstrom's Macroglobulinemia |
| Official title | A Phase II, Single-Arm Trial of Epratuzumab, an Anti-CD22 Humanized Antibody, in Patients With Waldenstrom's Macroglobulinemia |
| Lead sponsor | Gilead Sciences, Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Waldenstrom Macroglobulinemia |
| Intervention type | Drug |
| Interventions | Epratuzumab (hLL2- anti-CD22 humanized antibody) |
| Enrollment | 31 |
| Start date | Aug 1, 2004 |
| Primary completion | Dec 1, 2006 |
| Completion | Dec 1, 2006 |
| First posted | Jun 13, 2005 |
| Last update posted | Aug 19, 2021 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: